Discover Leishmaniasis (Kala-Azar) Therapeutic Pipeline H2 2016, Drug Profile and Major Key Players
Leishmaniasis (Kala-Azar) Pipeline Review, H2 2016, latest research study provides in depth analysis on Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) targeted pipeline therapeutics. Leishmaniasis (Kala-Azar) therapeutics industry report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history...
View full press release